Kim Forest Enterprise Co Ltd
TWSE:6645
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Country Average (20.9), the stock would be worth NT$-38.33 (386% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -7.3 | NT$13.4 |
0%
|
| Country Average | 20.9 | NT$-38.33 |
-386%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| TW |
|
Kim Forest Enterprise Co Ltd
TWSE:6645
|
812.4m TWD | -7.3 | -5.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
355.3B USD | 19.7 | 84.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.9B USD | 14.1 | 24.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.8B USD | 15.1 | 19.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.5B USD | 21.9 | 28 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81B USD | 15.3 | 18 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR | 42.4 | 38.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.2B AUD | 13.1 | 30.5 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 14.9 |
| Median | 20.9 |
| 70th Percentile | 30.2 |
| Max | 1 677.9 |
Other Multiples
Kim Forest Enterprise Co Ltd
Glance View
Kim Forest Enterprise Co., Ltd. engages in sale of instruments and reagents needed for new drug research and development. The company is headquartered in Taipei, New Taipei. The company went IPO on 2017-08-18. The firm operates through two segments. The Biomedical Experiment Products segment is engaged in provision of laboratory equipment, reagents, supplies and equipment maintenance services. Main products include filter type microplate spectrophotometer, polymerase chain reaction (PCR) molecular biology experiment related equipment and reagents, equipment and reagents for separating cell, protein and nucleic acids, rapid DNA detection reagent and others. The Biotechnology and Genetic Testing segment is engaged in provision of whole genome sequencing (WGS) and whole exome sequencing(WES) tumor analysis services, RNA sequencing analysis, and new drug development system and check services.
